Announced Thu, 30 Apr · 23:02 IST
Rubicon completes 85% acquisition of Arinna Lifesciences, makes it subsidiary
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.6%1-day move
₹964.10
prior close
₹970.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.2+0.4+0.6+0.6+4.6-1.5-1.6-0.4-1.3-2.1+34.3+41.0—
Up moveDown movePending
AI summary
Rubicon Research has completed the secondary acquisition of 85% stake in Arinna Lifesciences Limited on April 30, 2026, under the Share Purchase Agreement. Following this, Arinna Lifesciences becomes a subsidiary of Rubicon Research. This follows the company's earlier intimation dated April 15, 2026, regarding the deal.
Likely market impact
Acquisition expands Rubicon's portfolio. Arinna Lifesciences is now a subsidiary, likely to contribute to revenue and growth from the next quarter onwards.